Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.67 USD | +4.70% | +1.53% | +31.37% |
04-10 | Transcript : Chemomab Therapeutics Ltd. - Special Call | |
03-07 | Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 9.09M 12.41M |
---|---|---|---|---|---|
Net income 2024 * | -15M -20.48M | Net income 2025 * | -22M -30.04M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-10.7
x | P/E ratio 2025 * |
-8.53
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 4.97% |
Latest transcript on Chemomab Therapeutics Ltd.
1 day | +4.70% | ||
1 week | +1.53% | ||
Current month | -13.99% | ||
1 month | -13.12% | ||
3 months | +24.07% | ||
6 months | -9.46% | ||
Current year | +31.37% |
Managers | Title | Age | Since |
---|---|---|---|
Adi Mor
CEO | Chief Executive Officer | 43 | 11-09-21 |
Sigal Fattal
DFI | Director of Finance/CFO | 53 | 19-12-31 |
Chief Tech/Sci/R&D Officer | 56 | 22-11-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Neil Cohen
BRD | Director/Board Member | 60 | 20-03-31 |
Nissim Darvish
CHM | Chairman | 59 | 21-03-15 |
Claude Nicaise
BRD | Director/Board Member | 71 | 21-03-15 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 0.67 | +4.70% | 18 215 |
24-04-26 | 0.6399 | -2.90% | 23,560 |
24-04-25 | 0.659 | -1.64% | 11,541 |
24-04-24 | 0.67 | 0.00% | 3,426 |
24-04-23 | 0.67 | +1.53% | 7,157 |
Delayed Quote Nasdaq, April 29, 2024 at 02:06 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.37% | 9.09M | |
-2.78% | 103B | |
+1.39% | 95.28B | |
+1.46% | 22.15B | |
-15.80% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.08% | 16.05B | |
+5.13% | 13.68B | |
+33.65% | 12.17B |
- Stock Market
- Equities
- CMMB Stock